Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 7INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Dermatologic 1

Conditions

Recurrence 1Prostatic Neoplasms 1Multiple Myeloma 1Melanoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × tetrathiomolybdate × Clear all
NCT00352742 2008-10-28

A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

Attenuon

Phase 1/2 Terminated
46 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00405574 2008-01-30

Study of ATN-224 in Patients With Prostate Cancer

Attenuon

Phase 2 Unknown
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT00383851 2007-12-06

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

Attenuon

Phase 2 Unknown
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡